TY - JOUR
T1 - Safety and efficacy of elexacaftor/tezacaftor/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles
T2 - Interim results of an open-label phase 3 clinical trial
AU - Griese, Matthias
AU - Costa, Stefano
AU - Linnemann, Rachel W.
AU - Mall, Marcus A.
AU - McKone, Edward F.
AU - Polineni, Deepika
AU - Quon, Bradley S.
AU - Ringshausen, Felix C.
AU - Taylor-Cousar, Jennifer L.
AU - Withers, Nicholas J.
AU - Moskowitz, Samuel M.
AU - Daines, Cori L.
N1 - Funding Information:
Supported by research grants from the Ministry of Health, Labor and Welfare of Japan (201706009A) and the Advanced Research and Development Programs for Medical Innovation (18lk1403023h0001 and Advanced Research and Development Programs for Medical Innovation-Core Research for Evolutional Science and Technology; 16 gm1010003h0001).
PY - 2021/2/1
Y1 - 2021/2/1
UR - https://www.scopus.com/pages/publications/85096144059
U2 - 10.1164/rccm.202008-3176LE
DO - 10.1164/rccm.202008-3176LE
M3 - Letter
C2 - 32969708
AN - SCOPUS:85096144059
SN - 1073-449X
VL - 203
SP - 381
EP - 385
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 3
ER -